Background: Management of puberty in the hypogonadal girl remains controversial. Estrogens have profound effects on growth and development. Oral estrogens, the most widely used form, undergo first-pass metabolism in the liver and alter many aspects of hepatic function. Transdermal estrogens are not subject to first-pass metabolism and are effective at mimicking spontaneous pubertal estrogen levels resulting in normal pubertal development. Age-appropriate induction of puberty should be initiated at 12 to 13 years of age; delaying puberty any longer may compromise quality of life during adolescence. Estrogens should be started at a low dose, approximately one-tenth to one-eighth of the adult replacement dose, and then increased gradually over a period of 2 to 4 years. Generally, progestins are added after 2 years of estrogen therapy. With these treatment regimens, breast development typically proceeds at a normal pace; however, the effects on uterine dimensions are less clear. Concomitant treatment with oral dehydroepiandrosterone (or dehydroepiandrosterone sulfate) advances pubic hair development in the adolescent girl with panhypopituitarism. Conclusions: In the hypogonadal girl, puberty should be induced with very low doses of transdermal estradiol at 12 to 13 years of age with gradual dose escalations over 2 to 4 years. Combination estrogen/androgen therapy in girls with hypogonadism should be explored in future research.

Keywords:
Puberty, Girls, Estrogens, Progestin, Therapy
1.
Kiess W, Conway G, Ritzen M, Rosenfield R, Bernasconi S, Juul A, van Pareren Y, de Muinck Keizer-Schrama SMPF, Bourguignon JP: Induction of puberty in the hypogonadal girl – practices and attitudes of pediatric endocrinologists in Europe. Horm Res 2002;57:66–71.
2.
Drobac S, Rubin K, Rogol AD, Rosenfield RL: A workshop on pubertal hormone replacement options in the United States. J Pediatr Endocrinol Metab 2006;19:55–64.
3.
Leung KC, Johansson G, Leong GM, Ho KKY: Estrogen regulation of growth hormone action. Endocr Rev 2004;25:693–721.
4.
De Lignieres B, Basdevant A, Thomas G, Thalabard JC, Mercier-Bodard C, Conard J, Guyene TT, Mairon N, Corvol P, Guy-Grand B: Biological aspects of estradiol-17 beta in postmenopausal women: oral versus percutaneous administration. J Clin Endocrinol Metab 1986;62:536–541.
5.
Lobo RA: Absorption and metabolic effects of different types of estrogens and progestogens. Obstet Gynecol Clin North Am 1987;14:143–167.
6.
Illig R, DeCampo C, Lang-Muritano MR, Prader A, Torresani T, Werder EA, Willi U, Schenkel L: A physiological mode of puberty induction in hypogonadal girls by low dose transdermal 17 beta-oestradiol. Eur J Pediatr 1990;150:86–91.
7.
Ankarberg-Lindgren C, Elfving M, Albertson Wikland K, Norjavaara E: Nocturnal application of transdermal estradiol patches produces levels of estradiol that mimic those seen at the onset of spontaneous puberty in girls. J Clin Endocrinol Metab 2001;86:3039–3044.
8.
Piippo S, Lenko H, Kainulainen P, Sipila I: Use of percutaneous estrogen gel for induction of puberty in girls with Turner syndrome. J Clin Endocrinol Metab 2004;89:3241–3247.
9.
Powers MS, Schenkel L, Darley PE, Good WR, Balestra JC, Place VA: Pharmacokinetics and pharmacodynamics of transdermal dosage forms of 17 beta-estradiol: comparison with conventional oral estrogens used for hormone replacement. Am J Obstet Gynecol 1985;152:1099–1106.
10.
Rosenfield RL, Devine N, Hunold JJ, Mauras N, Moshang T Jr, Root AW: Salutary effects of combining early very low-dose systemic estradiol with growth hormone therapy in girls with Turner syndrome. J Clin Endocrinol Metab 2005;90:6424–6430.
11.
Chernausek SD, Attie KM, Cara JF, Rosenfeld RG, Frane J: Growth hormone therapy of Turner syndrome: the impact of age of estrogen replacement on final height. J Clin Endocrinol Metab 2000;85:2439–2445.
12.
Saenger P, Albertson Wikland K, Conway GS, Davenport M, Gravholt CH, Hintz R, Hovatta O, Hultcrantz M, Landin-Wilhelmsen K, Lin A, Lippe B, Pasquino AM, Ranke MB, Rosenfeld R, Silberbach M: Recommendations for the diagnosis and management of Turner syndrome. J Clin Endocrinol Metab 2001;86:3061–3069.
13.
Hogler W, Briody J, Moore B, Garnett S, Lu PW, Cowell CT: Importance of estrogen on bone health in Turner syndrome: a cross-sectional and longitudinal study using dual-energy x-ray absorptiometry. J Clin Endocrinol Metab 2004;89:193–199.
14.
Van Pareren YK, de Muinck Keizer-Schrama SM, Stijnen T, Sas TC, Jansen M, Otten BJ, Hoorweg-Nijman JJ, Vulsma T, Stokvis-Brantsma WH, Rouwe CW, Reeser HM, Gerver WJ, Gosen JJ, Rongen-Westerlaken C, Drop SL: Final height in girls with Turner syndrome after long-term growth hormone treatment in three dosages and low dose estrogens. J Clin Endocrinol Metab 2003;88:1119–1125.
15.
Bondy CA, Turner Syndrome Study Group: Care of girls and women with Turner syndrome: a guideline of the Turner syndrome study group. J Clin Endocrinol Metab 2007;92:10–25.
16.
Soriano-Guillen L, Coste J, Ecosse E, Leger J, Tauber M, Cabrol S, Nicolino M, Brauner R, Chaussain J-L, Carel J-C: Adult height and pubertal growth in Turner syndrome after treatment with recombinant growth hormone. J Clin Endocrinol Metab 2005;90:5197–5204.
17.
Ross JL, Cassorla FG, Skerda MC, Valk IM, Loriaux DL, Cutler GB Jr: A preliminary study of the effect of estrogen dose on growth in Turner’s syndrome. N Engl J Med 1983;309:1104–1106.
18.
Ross JL, Long LM, Skerda M, Cassorla F, Kurtz D, Loriaux DL, Cutler GB Jr: Effect of low doses of estradiol on 6-month growth rates and predicted height in patients with Turner syndrome. J Pediatr 1986;109:950–953.
19.
McDonnell CM, Coleman L, Zacharin MR: A 3-year prospective study to assess uterine growth in girls with Turner’s syndrome by pelvic ultrasound. Clin Endocrinol (Oxf) 2003;58:446–450.
20.
Paterson WF, Hollman AS, Donaldson MD: Poor uterine development in Turner syndrome with oral oestrogen therapy. Clin Endocrinol (Oxf) 2002;56:359–365.
21.
Doerr HG, Bettendorf M, Hauffa BP, Mehls O, Partsch CJ, Said E, Sander S, Schwarz HP, Stahnke N, Steinkamp H, Ranke MB: Uterine size in women with Turner syndrome after induction of puberty with estrogens and long-term growth hormone therapy: results of the German IGLU Follow-up Study 2001. Hum Reprod 2005;20:1418–1421.
22.
Snajderova M, Mardesic T, Lebl J, Gerzova H, Teslik L, Zapletalova J: The uterine length in women with Turner syndrome reflects the postmenarcheal daily estrogen dose. Horm Res 2003;60:198–204.
23.
Bannink EMN, Lequin M, de Muinck Keizer-Schrama SMPF: Results of estrogen therapy on uterine dimensions in Turner syndrome (abstract). Horm Res 2004;62(suppl 2):P3-456.
24.
Gravholt CH, Naeraa RW, Fisker S, Christiansen JS: Body composition and physical fitness are major determinants of the growth hormone-insulin-like growth factor axis aberrations in adult Turner’s syndrome, with important modulations by treatment with 17 beta-estradiol. J Clin Endocrinol Metab 1997;82:2570–2577.
25.
Gravholt CH, Naeraa RW, Nyholm B, Gerdes LU, Christiansen E, Schmitz O, Christiansen JS: Glucose metabolism, lipid metabolism, and cardiovascular risk factors in adult Turner’s syndrome. The impact of sex hormone replacement. Diabetes Care 1998;21:1062–1070.
26.
Ross JL, McCauley E, Roeltgen D, Long L, Kushner H, Feuillan P, Cutler GB Jr: Self-concept and behaviour in adolescent girls with Turner syndrome: potential estrogen effects. J Clin Endocrinol Metab 1996;81:926–931.
27.
Ross JL, Roeltgen D, Feuillan P, Kushner H, Cutler GB Jr: Effects of estrogen on nonverbal processing speed and motor function in girls with Turner’s syndrome. J Clin Endocrinol Metab 1998;83:3198–3204.
28.
Johnston DI, Betts P, Dunger D, Barnes N, Swift PG, Buckler JM, Butler GE: A multicentre trial of recombinant growth hormone and low dose oestrogen in Turner syndrome: near final height analysis. Arch Dis Child 2001;84:76–81.
29.
Quigley CA, Crowe BJ, Anglin DG, Chipman JJ: Growth hormone and low dose estrogen in Turner syndrome: results of a United States multi-center trial to near-final height. J Clin Endocrinol Metab 2002;87:2033–2041.
30.
Wit JM, Langenhorst VJ, Jansen M, Oostdijk W, van Doorn J: Dehydroepiandrosterone sulfate treatment for atrichia pubis. Horm Res 2001;56:134–139.
31.
Morales AJ, Haubrich RH, Hwang JY, Asakura H, Yen SS: The effect of six months’ treatment with a 100-mg daily dose of dehydroepiandrosterone on circulating sex steroids, body composition and muscle strength in age-advanced men and women. Clin Endocrinol (Oxf) 1998;49:421–432.
32.
Miller KK, Biller BMK, Beauregard C, Lipman JG, Jones J, Schoenfeld D, Sherman JC, Swearingen B, Loeffler J, Kliblanski A: Effects of testosterone replacement in androgen-deficient women with hypopituitarism: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab 2006;91:1683–1690.
33.
Bohnet HG: Gonadotropins: prolactin, and sex steroids in pubertal maturation of normal girl and agonadal subjects; in Givens JR (ed): Adolescence in Females. Chicago, Year Book Medical Publishers, 1985, pp 153–165.
34.
Apter D, Lenko HL, Perheentupa J, Soderholm A, Vihko R: Subnormal pubertal increase of serum androgens in Turner’s syndrome. Horm Res 1982;16:164–173.
35.
Gravholt CH, Sventrop B, Bennett P, Sandahl Christiansen J: Reduced androgen levels in adult Turner syndrome: influence of female sex steroids and growth hormone status. Clin Endocrinol 1999;50:791–800.
36.
Ross JL, Roeltgen D, Stefanatos GA, Feuillan P, Kushner H, Bondy C, Cutler GB Jr: Androgen-responsive aspects of cognition in girls with Turner syndrome. J Clin Endocrinol Metab 2003;88:292–296.
© 2007 S. Karger AG, Basel
2007
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.